Stock CAMX CAMURUS AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Camurus AB

Equities

CAMX

SE0007692850

Pharmaceuticals

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-07-08 pm EDT 		5-day change 1st Jan Change
615.5 SEK +3.19% Intraday chart for Camurus AB +3.62% +14.41%
Jun. 25 Camurus Announces the Publication in JAMA Network Open of A New Post H Holes Analysis from A 24-Week Randomized, Double-Blind, Phase 3 Study CI
May. 23 Camurus' Rare Growth Disorder Drug Accepted for Review in EU MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 4,363 10,109 8,268 14,000 29,926 36,091 - -
Enterprise Value (EV) 1 4,032 9,673 7,882 13,461 28,760 33,923 32,712 30,629
P/E ratio -13.6 x -58.6 x -90.8 x 260 x 71.7 x 106 x 35.4 x 19.2 x
Yield - - - - - - - -
Capitalization / Revenue 41.3 x 30.1 x 13.8 x 14.6 x 17.4 x 18.9 x 11.8 x 8.56 x
EV / Revenue 38.2 x 28.8 x 13.1 x 14.1 x 16.8 x 17.8 x 10.7 x 7.26 x
EV / EBITDA -11.5 x -49.9 x -92.3 x 159 x 53.3 x 79.7 x 25.4 x 14.8 x
EV / FCF -9.35 x -39.9 x -53.1 x 136 x 48.2 x 147 x 33.5 x 17 x
FCF Yield -10.7% -2.5% -1.88% 0.74% 2.07% 0.68% 2.99% 5.88%
Price to Book 6.91 x 11.9 x 9.67 x 14 x 20.7 x 13.9 x 9.48 x 6.22 x
Nbr of stocks (in thousands) 51,637 54,234 54,829 55,423 55,624 58,637 - -
Reference price 2 84.50 186.4 150.8 252.6 538.0 615.5 615.5 615.5
Announcement Date 2/12/20 2/11/21 2/16/22 2/14/23 2/15/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 105.6 336 601 956.3 1,717 1,906 3,047 4,216
EBITDA 1 -351 -193.7 -85.37 84.89 539.9 425.7 1,287 2,070
EBIT 1 -360 -205.2 -111 71.96 525.9 408.8 1,268 2,047
Operating Margin -340.91% -61.08% -18.47% 7.52% 30.63% 21.45% 41.61% 48.56%
Earnings before Tax (EBT) 1 -361.6 -206.6 -111.8 73.12 549.3 441.4 1,296 2,073
Net income 1 -289.9 -167.3 -90.45 55.55 431.4 339.1 1,042 1,716
Net margin -274.53% -49.78% -15.05% 5.81% 25.13% 17.79% 34.21% 40.7%
EPS 2 -6.230 -3.180 -1.660 0.9700 7.500 5.809 17.39 32.07
Free Cash Flow 1 -431.4 -242.2 -148.4 99.29 596.8 230.5 976.9 1,800
FCF margin -408.56% -72.07% -24.69% 10.38% 34.76% 12.09% 32.06% 42.69%
FCF Conversion (EBITDA) - - - 116.97% 110.53% 54.15% 75.91% 86.93%
FCF Conversion (Net income) - - - 178.74% 138.32% 67.98% 93.73% 104.88%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/12/20 2/11/21 2/16/22 2/14/23 2/15/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 183 220.3 226.7 241.4 268 284 674.3 384 374.6 390 447.5 504.5 606.6 650 690
EBITDA 1 -10.1 7.928 10.04 44.28 22.64 77.6 379.4 107.5 -24.65 82.35 99.96 124.4 175 - -
EBIT 1 -18 4.791 6.915 41.37 18.88 74.34 376.1 104 -28.54 78.66 94.81 112.4 163.9 200 275
Operating Margin -9.84% 2.17% 3.05% 17.14% 7.04% 26.17% 55.77% 27.1% -7.62% 20.17% 21.19% 22.28% 27.01% 30.77% 39.86%
Earnings before Tax (EBT) 1 -18.44 4.498 6.622 41.51 20.49 76.87 380.6 109.8 -18.01 96.86 95.15 112.1 195.4 214 289
Net income 1 -14.02 -0.752 8.239 35 13.07 58.83 301.4 86.4 -15.21 77.86 81.38 95.36 136.1 169 228
Net margin -7.66% -0.34% 3.63% 14.5% 4.88% 20.71% 44.7% 22.5% -4.06% 19.97% 18.18% 18.9% 22.43% 26% 33.04%
EPS 2 -0.2600 -0.0100 0.1400 0.6100 0.2300 1.020 5.240 1.500 -0.2700 1.320 1.406 1.524 2.651 2.950 3.920
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 2/16/22 5/12/22 7/15/22 11/10/22 2/14/23 5/10/23 7/18/23 11/9/23 2/15/24 5/8/24 - - - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 331 436 386 539 1,165 2,168 3,379 5,462
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -431 -242 -148 99.3 597 231 977 1,800
ROE (net income / shareholders' equity) -65.6% -22.6% -10.7% 6.03% 34.7% 16.9% 36% 42%
ROA (Net income/ Total Assets) - -18.4% -8.51% 4.65% 26.9% 14.4% 23.3% 25.1%
Assets 1 - 908.1 1,063 1,194 1,607 2,355 4,473 6,837
Book Value Per Share 2 12.20 15.60 15.60 18.10 26.00 44.20 64.90 98.90
Cash Flow per Share - - - - - - - -
Capex 1 4.63 3.33 4.94 1.91 10.1 21.6 23 26.2
Capex / Sales 4.39% 0.99% 0.82% 0.2% 0.59% 1.13% 0.76% 0.62%
Announcement Date 2/12/20 2/11/21 2/16/22 2/14/23 2/15/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Camurus AB

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
615.5 SEK
Average target price
621.5 SEK
Spread / Average Target
+0.97%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CAMURUS AB Stock Camurus AB
+14.41% 3.42B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+57.48% 827B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.18% 350B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.37% 319B
ABBVIE INC. Stock AbbVie Inc.
+7.45% 294B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.62% 240B
NOVARTIS AG Stock Novartis AG
+14.55% 221B
ROCHE HOLDING AG Stock Roche Holding AG
-0.33% 219B
AMGEN INC. Stock Amgen Inc.
+8.14% 167B
PFIZER, INC. Stock Pfizer, Inc.
-2.99% 158B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CAMX Stock
  4. Financials Camurus AB